Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Institute for Neurodegenerative Disorders |
---|---|
Information provided by: | Institute for Neurodegenerative Disorders |
ClinicalTrials.gov Identifier: | NCT00354003 |
The overall goal of the study is to evaluate how research participants in Parkinson Disease studies that include brain imaging with a dopamine transporter ligand choose to receive the imaging data and what is the impact of the imaging data information on the management of their symptoms.
Condition | Intervention |
---|---|
Parkinsonian Syndrome Parkinson |
Behavioral: A series of questionnaires |
Study Type: | Observational |
Study Design: | Case-Only, Prospective |
Official Title: | Impact of Disclosure of Dopamine Transporter Imaging Studies in PD Clinical Trials |
Estimated Enrollment: | 800 |
Study Start Date: | July 2006 |
Estimated Study Completion Date: | August 2008 |
Research participants who previously underwent ß-CIT imaging will be contacted by the staff at IND to enquire whether they would like to receive their ß-CIT scan data. After signing a Research Participant Information and Consent Form, all research participants will be asked to complete a questionnaire prior to receipt of their imaging data. Those research participants requesting imaging data will be sent their data by IND and may review their data with IND (by phone) and/ or with their study investigator. All research participants will be asked to respond to a second questionnaire after receiving their imaging data and to a third study questionnaire approximately six weeks following receipt of their imaging data.
Ages Eligible for Study: | 21 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Research participants who previously underwent ß-CIT imaging
Inclusion Criteria:
Exclusion Criteria:
-
Contact: Susan Harman | 203-401-4300 | sharman@indd.org |
United States, Connecticut | |
Institute for Neurodegenerative Disorders | Recruiting |
New Haven, Connecticut, United States, 06510 | |
Contact: Susan Harman 203-401-4300 sharman@indd.org | |
Contact: Susan Mendick 203-401-4300 smendick@indd.org | |
Principal Investigator: Kenneth Marek, MD | |
Sub-Investigator: Danna Jennings, MD |
Principal Investigator: | Kenneth Marek, MD | Institute for Neurodegenerative Disorders |
Responsible Party: | IND ( Ken Marek, MD ) |
Study ID Numbers: | IMAG-DIS 01 |
Study First Received: | July 17, 2006 |
Last Updated: | April 24, 2008 |
ClinicalTrials.gov Identifier: | NCT00354003 |
Health Authority: | United States: Food and Drug Administration |
Parkinson Imaging |
Dopamine Ganglion Cysts Movement Disorders Parkinson Disease Basal Ganglia Diseases |
Central Nervous System Diseases Parkinsonian Disorders Neurodegenerative Diseases Brain Diseases |
Pathologic Processes Disease Syndrome Nervous System Diseases |